A Study to Evaluate the Pharmacokinetics and Safety of IN-M00007 and IN-R00007 in Healthy Adult Volunteers

NCT07311811 | Not Yet Recruiting Phase 1

• 1 other identifier: IN_RVZ_104
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to evaluate the Pharmacokinetic (PK) characteristics and safety after a single oral dose administration of IN-M00007 and IN-R00007 in healthy adult volunteers

Conditions

Healthy Volunteers

Outcome Measures

Primary Outcomes (4)

• PK parameter

  AUCt of Rosuvastatin

  Up to 48 hours

• PK parameter

  Cmax of Rosuvastatin

  Up to 48 hours

• PK parameter

  AUCt of Ezetimibe

  Up to 72 hours

• PK marameter

  Cmax of Ezetimibe

  up to 72 hours

Study Arms (2)

Sequence A

EXPERIMENTAL

R → T R: IN-R00007, T: IN-M00007

Drug: IN-R00007; Drug: IN-M00007

Sequence B

EXPERIMENTAL

T → R R: IN-R00007, T: IN-M00007

Drug: IN-R00007; Drug: IN-M00007

Interventions

IN-R00007 DRUG

Single dose

Sequence A; Sequence B

IN-M00007 DRUG

Single dose

Sequence A; Sequence B

Eligibility Criteria

• Age: 19 Years - 59 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy adult volunteers aged ≥ 19 and \< 60 years at screening
• Body mass index(BMI) in the range of 18.0 and 30.0 kg/㎡
• Body weight ≥ 50kg for male
• Body weight ≥ 45kg for female
• Subjects who do not have significant congenital or chronic diseases and without pathological symptoms or findings based on medical examinations(if necessary, EEG, ECG, chest X-ray, gastroscopy or gastrointestinal radiographic tests)
• Determined by the investigator to be eligible for study participation based on the results of screening tests (e.g. hematology test, blood chemistry test, serology test, urinalysis, pregnancy diagnostic tests) conducted according to the IP characteristics
• Subjects who voluntarily signed the consent form after receiving detailed explanation and understanding about purpose, details, characteristics of the IP and anticipated adverse events of the study
• Subjects who agree to use highly effective methods of contraception(excluding hormonal methods) to preclude the possibility of pregnancy of themselves or their spouse/partner from the first IP administration until 14 days after the last administration, and who agrees not to donate sperm or ovum during this period
• Highly effective contraceptive methods: intrauterine device(IUD), bilateral tubal ligation, a partner who has undergone vasectomy, or sexual abstinence However, periodic abstinence(calendar method, symptothermal method, post-ovulation method), withdrawal intercourse(coitus interruptus), spermicide methods, lactational amenorrhea method, and simultaneous use of female and male condoms are not considered contraceptive methods

You may not qualify if:

• Subjects who have taken drugs which can induce(e.g, Barbiturates) or inhibit drug metabolism enzyme within 30 days prior to the start of the study(first IP administration day) or have taken medications that may affect this study within 10 days prior to the start of the study(first IP administration day)
• Subjects who have participated in any other clinical study or bioequivalence study and administered IP within 6 months
• Subjects who have donated whole blood within 8 weeks prior to the start of the study(first IP administration day) or have donated component blood within 2 weeks prior to the start of the study(first IP administration day)
• Subjects with a history of gastrointestinal resection that may affect drug absorption(excluding appendectomy and hernia operation)
• Subjects meeting following conditions within 1 month prior to the start of the study(first IP administration day)
• Alcohol consumption \> 21 glasses per week for male
• Alcohol consumption \> 14 glasses per week for female
• Subjects with the following diseases
• Subjects with hypersensitivity to the ingredient or components of this drug
• Subjects with active liver disease or those with persistently elevated serum aminotransferase levels of unknown cause
• Subjects with muscular disorders
• Subjects receiving concomitant administration with cyclosporine
• Subjects with severe renal impairment or kidney dysfunction
• Subjects with a hereditary problems, for example, galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
• Subjects with a clinically significant history of mental illness

Sponsors & Collaborators

• HK inno.N Corporation: lead

Study Sites (1)

H PLUS Yangji Hospital, Clinical Trial Center

Seoul, South Korea

Location

Study Officials

• Hyeonggeon Kim

  H Plus Yangji Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Heeju Ahn

CONTACT

+82 31-5176-4662; heeju.ahn21@inno-n.com

Yugyeong Park

CONTACT

+82 31-5176-4661; yugyeong.park@inno-n.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 14, 2025
• First Posted: December 31, 2025
• Study Start: January 1, 2026
• Primary Completion: March 1, 2026
• Study Completion: April 1, 2026
• Last Updated: December 31, 2025

Record last verified: 2025-12

Locations

KR (1)